FDA’s top generic drug official urges firms to complete nitrosamine risk assessments
Regulatory NewsJoanne S. Eglovitch
ComplianceContaminantsGenericsNitrosaminesNorth AmericaQuality Assurance and ControlRegulatory Intelligence/PolicyUS Food and Drug Administration (FDA)